Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure drug may boost red blood cells and organ health

NCT ID NCT07478575

Knowledge-focused Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines whether SGLT2 inhibitors, a type of diabetes drug, can improve red blood cell production and heart/kidney function in people with chronic heart failure. Researchers will compare blood tests, heart ultrasound measures, and clinical outcomes between 85 patients who started the drug and a matched group who did not, over 12 months. The goal is to understand how these drugs might help beyond blood sugar control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 85 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with chronic heart failure on guideline-directed medical therapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of chronic heart failure * Receiving guideline-directed medical therapy for heart failure for at least 3 months prior to inclusion * Age ≥18 years Exclusion Criteria: * Incomplete or missing data in electronic medical records * Acute cardiac event within 3 months prior to baseline * Active malignancy or hematological disease affecting erythropoiesis * Use of erythropoiesis-stimulating agents or regular erythrocyte transfusions during the observation period * Severe renal insufficiency (eGFR \<15 mL/min/1.73m²) * Severe liver insufficiency (AST/ALT \>3× upper limit of normal, bilirubin \>2× upper limit of normal) * Known allergy to any SGLT2 inhibitor component * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia congestive heart failure heart failure kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Heart failure Renal insufficiency

Contacts and locations

Locations

  • University Medical Centre Ljubljana

    Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.